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Objective: Previous reports from select hypertensive patients suggest that atherosclerotic renovascular disease (RVD) is
rapidly progressive and associated with a decline in kidney size and kidney function. This prospective, population-based
study estimates the incidence of new RVD and progression of established RVD among elderly, free-living participants in
the Cardiovascular Health Study (CHS).
Method: The CHS is a multicenter, longitudinal cohort study of cardiovascular risk factors, morbidity, and mortality
among men and women aged >65 years old. From 1995 through 1996, 834 participants underwent renal duplex
sonography (RDS) to define the presence or absence of significant RVD. Between 2002 and 2005, a second RDS study
was performed in 119 participants (mean study interval, 8.0  0.8 years). Significant RVD was defined as hemodynam-
ically significant stenosis (renal artery peak systolic velocity [RA-PSV] exceeding 1.8 m/s) or renal artery occlusion.
Prevalent RVD was significant RVD at the first RDS, and incident disease was defined as new significant RVD at the
second RDS. Significant change of RVD was defined as a change in RA-PSV of greater than two times the standard
deviation of expected change over time, regardless of hemodynamic significance or progression to renal artery occlusion.
Results: The second RDS study cohort included 119 CHS participants with 235 kidneys (35% men; mean age, 82.8 
3.4). On follow-up, no prevalent RVD (n  13 kidneys; 6.0%) progressed to occlusion. Twenty-nine kidneys without
RVD at the first RDS demonstrated significant change in PSV at the second RDS; including nine kidneys with new
significant RVD (8 new stenoses; 1 new occlusion). Controlling for within-subject correlation, the overall estimated
change in RVD among all 235 kidneys was 14.0% (95% confidence interval [CI], 9.2% to 21.4%), with progression to
significant RVD in 4.0% (95% CI, 1.9% to 8.2%). Longitudinal increase in diastolic blood pressure and decrease in renal
length were significantly associated with progression to new (ie, incident) significant RVD but not prevalent RVD.
Conclusions: This is the first prospective, population-based estimate of incident RVD and progression of prevalent RVD
among free-living elderly Americans. In contrast to previous reports among select hypertensive patients, CHS partici-
pants with a low rate of clinical hypertension demonstrated a significant change of RVD in only 14.0% of kidneys on
follow-up of 8 years (annualized rate, 1.3% per year). Progression to significant RVD was observed in only 4.0%
(annualized rate, 0.5% per year), and no prevalent RVD progressed to occlusion. (J Vasc Surg 2006;44:955-63.)There are no prospective, population-based studies
that define the natural history of atherosclerotic renovascu-
lar disease (RVD). Available information regarding RVD is
extrapolated from angiographic case series and ultrasound
examinations from retrospective reviews or from prospec-
tive studies of select hypertensive patients. The quality of
these studies and the interpretation of their data vary
widely. Most commonly, authors consider anatomic pro-
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doi:10.1016/j.jvs.2006.07.031gression of RVD a certainty, one that is associated with an
inevitable decline in kidney size and kidney function. This
view is frequently cited to support intervention for RVD
whenever discovered.1
In contrast to previous reports, this prospective,
population-based study estimated the incidence of new
RVD and the progression of established RVD among par-
ticipants in the Cardiovascular Health Study (CHS). The
CHS is a longitudinal, population-based study of coronary
heart disease and stroke in elderly men and women.2 Renal
duplex sonography (RDS) was applied to the CHS Forsyth
County, North Carolina, cohort to determine the presence
of RVD in these elderly, free-living, community-dwelling
participants.3 A second RDS was applied to surviving CHS
participants 8 years later. The specific points of interest
included (1) the incidence of new significant RVD defined
during the study period, (2) the progression of established
RVD on follow-up, and (3) the relationship of incident and
prevalent RVD with changes in blood pressure, excretory
renal function, and kidney length.
METHODS
Subjects. The incidence of new RVD and the progres-
sion of established RVDwere estimated by two RDS exam-
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the CHS. The CHS is an observational, population based
longitudinal study of risk factors for coronary heart disease
and stroke in adults aged 65 years.2 The sampling strat-
egy, baseline characteristics, atherosclerotic risk factors,
and clinical examination have been described in detail.4-10
Briefly, the primary aim of the CHS is to identify and assess
factors related to the onset of coronary heart disease and
stroke in this age group. The CHS study design included
four field centers from four different US communities
(Forsyth County, NC; Sacramento County, Calif; Wash-
ington County, Md; and Allegheny County, Pa) to recruit
and examine not less than 1250 men and women during
the first study year beginning June 1989, for a total of at
least 5000 subjects study wide.
Each community sample was obtained with a two-step
process from Medicare eligibility lists of the Health Care
Financing Administration. These lists were sampled from a
random start to produce sampling frames of approximately
5000 potential participants in each community. Random
samples were selected from the sampling frames with a
customized program to produce a Forsyth County cohort
with a 62:38 female/male ratio in each of four age strata,
with the following distribution within each baseline strata:
65 to 69 years, 30%; 70 to 74 years, 29%; 75 to 79 years,
19%; and 80 years, 22%.
Those eligible to participate included all persons living
in each sampled household who were aged65 years, were
not institutionalized, were expected to remain in the area
for at least a 3-year follow-up period, were able to give
informed consent, and did not require a proxy respondent
at baseline. Excluded were individuals who were undergo-
ing hospice treatment, radiation therapy or chemotherapy
for cancer, or who were wheelchair bound. The overall
Forsyth County participation rate was 61%. Those initially
sampled comprised 70% of the overall CHS cohort, with
the remaining 30% recruited from a shared household with
the index participant.11
Between September 1992 and May 1993, 236 addi-
tional African American participants were recruited into the
Forsyth County cohort with the same sampling and recruit-
ment techniques. These techniques provided the following
Forsyth County CHS enrollment distribution within each
age strata: 65 to 69 years, 32%; 70 to 74 years, 29%; 75 to
79, 22%; and 80 years, 17%.
Participants from the Forsyth county cohort of the
CHS were recruited for the first RDS between January
1995 and February 1997. The presence of significant RVD,
defined as60% diameter-reducing renal artery stenosis or
occlusion, was estimated using RDS. These results were
used to define the prevalence of significant RVD. Attempts
were made to contact all 610 surviving Forsyth County
CHS participants using contact information obtained from
the last annual CHS follow-up exam in 1999. Of the 610,
494 were contacted and 119 (20%) were recruited for the
second RDS between July 2002 and June 2005. Of the
remaining 491 CHS participants, 375 deferred or declined
to participate because of prior poor health or other reasons,and 116 participants could not be contacted. Both studies
were approved by the Wake Forest University Human
Subjects Review Committee.
Renal duplex sonography. As an ancillary study to
the CHS, funded through the National Institute of Diabe-
tes, Digestive and Kidney Diseases, and the General Clini-
cal Research Center (GCRC), RDS was used to study CHS
participants in the Forsyth County cohort. At the first RDS
examination, participants scheduled for routine annual ex-
amination were contacted by telephone and informed of
the ancillary project. Most of the first RDS studies were
performed with the annual examination. Survivors among
the Forsyth County CHS cohort were contacted by tele-
phone and informed of the second RDS. The second RDS
was performed through the GCRC.
The technique of RDS has been described in de-
tail.3,12-13 Briefly, after an overnight fast and written in-
formed consent, the CHS participant was placed in the
supine position and a 2.25 MHz or 3.0 MHz ultrasound
probe was coupled to the abdominal skin with acoustic gel
3 or 4 cm inferior to the xiphoid process. Sagittal B-mode
scan images were obtained of the upper abdominal aorta,
celiac axis, and superior mesenteric arteries. Identification
of these three arteries was confirmed by the characteristic
fasting waveforms from each vessel.
After a sagittal aortic and superior mesenteric artery
signal was obtained, the probe was rotated 90° to obtain a
B-mode scan image of the aorta and proximal superior
mesenteric artery in cross-section. The left renal vein was
identified in longitudinal section. Using the left renal vein
as a reference, the aortic origins of the main renal arteries
were identified. While maintaining an angle of insonation
of 60°, Doppler samples were taken from each renal
artery from aortic origin to the renal hilum, for a total of
approximately 10 Doppler sample sites per renal artery.
Renal artery peak systolic velocity (RA-PSV) and end-
diastolic velocity were estimated from the spectral analysis
of the Doppler-shifted signals. After Doppler interrogation
in the supine position, RA-PSV was estimated from a flank
approach with the participant in right or left lateral decub-
itus positions. B-mode scan imaging of each kidney deter-
mined the greatest longitudinal kidney length. The RDS
study was considered negative or positive for significant
RVD or inadequate for interpretation according to the
following criteria: (1) RDS was negative for significant
RVD when RA-PSV from aortic origin to renal hilum was
1.8 m/s, (2) RDS was positive for hemodynamically
significant RVD when there was a focal increase in RA-PSV
1.8 m/s (60% renal artery diameter-reducing stenosis)
or no Doppler signal was obtained from an imaged artery
(renal artery occlusion), (3) RDS was technically inade-
quate for interpretation when RA-PSV could not be deter-
mined from the aortic origin to the renal hilum.
As a pilot study, we reviewed RDS results from 108
patients with repeat studies performed within a 12-month
period at the Clinical Vascular Laboratory at Wake Forest
University School of Medicine. The PSV proved highly
reliable (Pearson correlation coefficient, r  0.95). RDS
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absence of hemodynamically significant renal artery steno-
sis or occlusion demonstrated complete agreement. These
data demonstrated that PSV and interpretation of PSV for
the presence or absence of significant RVD have excellent
repeatability.
This study design used previously published estimates
of disease progression to presume a 5% per year progres-
sion.14 To detect progression of 2.5% per year with 80%
power required 300 CHS participants for two RDS exam-
inations over the 8-year period of study. Prevalent RVD
was present at the first RDS. Incident disease was defined as
new hemodynamically significant stenosis or occlusion on
follow-up at second RDS. Significant change of RVD was
considered present when PSV changed more than two
times the estimated standard deviation of the mean change
over time or RDS progressed to hemodynamically signifi-
cant RVD.
Statistical analysis. After study data were keyed and
verified, RDS results were matched with participant data
provided by the CHS Coordinating Center. Variability of
the expected longitudinal change in PSV was estimated
using data collected in the Clinical Vascular Laboratory on
an independent group of 435 patients undergoing serial
RDS without intervention. From these 435 patients, 281
age-matched patients (mean 75.6  6.5 years) underwent
two or more RDS examinations (mean, 2.9 RDS; median,
2 RDS) between 1997 and 2003 (median follow-up, 2.0
years; range, 0.2 to 6.0 years). Random coefficient regres-
sion models were applied to this age-matched patient
group to estimate the mean and variance of the annualized
change in maximum RA-PSV.15
To estimate the expected progression for an individual
CHS participant, the annualized rate estimated from the
reference cohort was multiplied by the time (in years)
between the initial and follow-up CHS RDS exams. By
convention, a change in PSV over the time course exceed-
ing two times the estimated standard deviation of the mean
change in absolute value (renal artery [RA]-PSV change of
45 cm/s) was considered significant. Progression to renal
artery occlusion was also considered significant.
Kidney-based estimates of change in RVD and univar-
iate examination of associations between risk factors and
change in RVDwere obtained using generalized estimating
equation models that controlled for within-person correla-
tion.16 Changes in renal length were examined using re-
peated measures linear regression models that controlled
for within-person correlation.17
RESULTS
Between January 1995 and February 1997, 1245 For-
syth County participants returned to the CHS Field Center
for annual examination. Among returning participants, 870
gave consent for their first RDS, providing 69.9% recruit-
ment efficiency. The comparison of CHS participants with
nonparticipants and the prevalence of RVD among recruited
CHS participants have been described in detail.3,11,18 Of
834 participants successfully studied with RDS, 57 (6.8%)had significant RVD at the first examination. Significant
RVD was unilateral in 50 patients and bilateral in seven. Of
64 renal arteries with significant RVD, 57 kidneys had
hemodynamically significant renal artery stenosis and seven
arteries were occluded. Prevalent RVD had no significant
association with either gender or ethnicity, but did demon-
strate a significant and independent association with in-
creasing participant age, decreased high-density lipoprotein
cholesterol, and increased systolic blood pressure.3
Of the 834 technically satisfactory first RDS examina-
tions, 610 surviving CHS participants were invited to re-
turn for a second RDS examination. Between 2002 and
2005, 119 (14.3%) from the first RDS cohort returned for
a second RDS examination (mean study interval, 8.0 0.8
years). The repeat study cohort was a mean age of 82.8 
3.4 years at the second RDS examination. The group
included 65% women and 35% men, and 77% were white
and 23% were African American. Table I defines atheroscle-
Table I. Demographics and baseline atherosclerotic risk
factors among 610 Cardiovascular Health Study
participants
Variable/Definition*
Recruited
(n  119)
Non-recruited
(n  491) P
Age in years† 81.9  3.5 83.3  4.4 .001
Race .870
African-American (%) 27 (33) 108 (22)
White or other (%) 92 (77) 383 (78) —
Gender .781
Female (%) 77 (65) 311 (63) —
Male (%) 42 (35) 180 (37) —
Blood pressure (mm HG)
Systolic 134  19 136  20 .489
Diastolic 72  9 72  10 .775
Clinical hypertension 14 (12) 64 (13) .710
SBP 60 mm Hg or
DBP 95 mm Hg or
Anti-hypertensive
meds (%) 65 (55) 251 (51) .493
Statin use (%) 10 (8) 28 (6) .274
ACE inhibitor use (%) 6 (5) 51 (10) .072
Diabetes mellitus (%)‡ 19 (16) 71 (14) .678
Cigarette smoking†
Ever 49 (41) 222 (45) 0.427
Hypercholesterolemia
Total cholesterol
(mg/dL) 197  31 205  38 0.020
Elevated LDL-C
(mg/dL) 123  32 128  33 0.140
Decreased HDL-C
(mg/dL) 53  15 54  13 0.281
Obesity† (%) 130% ideal
body weight 37 (31) 156 (32) 0.886
SBP, Systolic blood pressure; DPB, diastolic blood pressure, ACE, an-
giotensin converting enzyme; LDL-C, low-density lipoprotein choles-
terol; HDL-C, high-density lipoprotein cholesterol.
*Data are presented as % or mean  SD.
†At November 1, 2002.
‡Diabetes mellitus is defined as fasting glucose 140 mg/dL or 2-hr
post-glucose load 200 mg/dL or insulin or oral hypoglycemic agent.rotic risk factors that were examined and compares surviv-
s.
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with those who did not.
Among 235 kidneys with a technically satisfactory RDS
examination, significant RVD was present at the first exam-
ination in 13 kidneys (6%; 95% confidence interval [CI],
3.2% to 11.2%). No significant change of prevalent RVD
was found on the second RDS study. No 60% diameter-
reducing renal artery stenosis at the first examination pro-
gressed to occlusion on the second RDS.
At the second RDS, new hemodynamically significant
RVDwas identified in nine kidneys (incident disease: 8 new
renal artery stenoses; 1 new renal artery occlusion). A signifi-
cant increase in RA-PSV was observed in 29 kidneys, in-
cluding the nine cases of incident RVD. A significant de-
crease in PSV was observed in 23 kidneys, including six
kidneys with velocities indicative of RVD (ie, PSV 1.8
m/s) at the initial RDS exam had PSV values 1.8 m/s at
follow-up exam.
In patients with repeat RDS, mean blood pressure
was 136  21/80  9 mm Hg at first RDS and 145 
23/72  12 mm Hg at the second examination. Mean
serum creatinine concentration was 1.0  0.3 mg/dL at
first RDS vs 1.3  0.3 mg/dL at follow-up. This reflected
a mean increase of 0.29 mg/dL (SEM, 0.04; 95% CI, 0.21
to 0.37). For 228 kidneys with length measurements at the
first and second RDS, maximum pole-to-pole renal length
decreased by 0.37  1.17 cm (SEM, 0.9; 95% CI, 0.20 to
0.55). By univariate analysis, longitudinal increase in dia-
stolic blood pressure (P .01) and decrease in renal length
(P .001) were significantly associated with incident RVD
(ie, progression to hemodynamically significant RVD) but
not prevalent RVD or significant change in RVD that
equated to 60% renal artery stenosis or occlusion.
DISCUSSION
To our knowledge, this is the first prospective,
population-based estimate of incident RVD and progres-
sion of prevalent RVD among free-living, elderly Ameri-
cans. Anatomic progression to hemodynamically significant
RVD was observed in only 4% of participants on a mean
follow-up of 8 years, an annualized progression rate of
Table II. Retrospective angiographic studies of medically
Author Year
Patients
(n)
Renal
arteries
(n)
Mean
follow-up
(months)
Anatom
progressi
(% patien
Wollenweber19 1968 109 252 42 59 
Meaney20 1968 39 78 34 36 
Schreiber21 1984 85 126 52 44 
Tollefson22 1991 48 — 54 53† 
Crowley23 1998 1178 — 30 11 
Chabova24 2000 68 — 39 — 
SCr, Serum creatinine; GFR, glomerular filtration rate; NS, not significant.
*1.5 cm discrepancy in renal length.
†Percentage of renal arteries with baseline stenosis or stenosis in follow-up.
‡SCr increased among patients with anatomic progression to 75% stenosi0.5% per year. Moreover, no cohort participant with signif-icant RVD at the first examination progressed to renal
artery occlusion on follow-up.
These study results contrast sharply with retrospective
angiographic case series, prospective angiographic studies,
and prospective duplex studies, which describe progression
of RVD. Retrospective reports of serial aortography and
progression of RVD are summarized in Table II.19-24 Con-
sidered collectively, the retrospective angiographic case
series suggest that atherosclerotic lesions of the renal arter-
ies demonstrate significant anatomic progression over rela-
tively short periods of follow-up. On mean follow-up of
44 months, roughly one third of renal artery lesions dem-
onstrated radiographic progression, and 10% progressed to
occlusion.
Although these early studies describe a dramatic pro-
gression of RVD, the application of these observations to
the population at large is probably flawed. Each of these
studies reported on highly select groups of patients with
significant clinical disease that warranted serial aortogra-
phy. With the exception of the report by Crowley et al,23
renovascular hypertension was suspected in nearly all of the
subjects and worsening hypertension was themost frequent
indication for repeat study. Consequently, it is doubtful
that the same rate of progression would apply to all indi-
viduals with RVD.
Prospective angiographic clinical studies of RVD are
summarized in Table III.25-29 More than 25 years ago,
Dean et al24 reported on patients with renovascular hyper-
tension randomized to medical management or surgical
revascularization. Randomized to medical management
were 41 patients with high grade atherosclerotic renal
artery stenosis and renovascular hypertension proven by
renal vein renin assay, or split renal function studies, or
both. These patients were monitored for an average of
44 months, during which 17 patients (41%) crossed over
to the surgical arm. Although 15 of the 17 patients had
controlled hypertension, each patient had declining renal
function as defined by a 10% loss of renal length, a 100%
increase in serum creatinine level, or a 50% reduction in
measured glomerular filtration rate (GFR) or creatinine
clearance (CrCl). Among the patients treated medically, 22
aged atherosclerotic renal artery stenosis
Progression
to occlusion
(% arteries)
Blood
pressure
change
Decrease in
renal length
(% patients)
SCr
increase
(% patients)
GFR
decline
(% patients)
— — — — —
4 — — — —
11 NS 46* 38 —
9† — —  —  —
0.3 — — ‡ —
— NS — 15 —man
ic
on
ts)(54%) had no increase in serum creatinine, 47% of those
er we
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no significant change, 37% had a50% decline in GFR, and
2% (1 patient) experienced a 50% decline. Interestingly,
four patients (13%) demonstrated improvement in mea-
sured CrCl or GFR when measured serially. Despite the
severity of renovascular disease, the decline in renal func-
tion was variable, with 97% of patients losing 50% of
measured GFR.
A recent prospective study by Pillay et al29 described
the change in blood pressure and serum creatinine among
patients with RVD. In this multicenter, nonrandomized,
observational study, 98 patients were noted to have 50%
renal artery stenosis during aortography obtained to evalu-
ate peripheral vascular disease. Complete data were avail-
able for 85 patients during a minimum 2-year follow-up.
Among these, 64 patients with unilateral stenosis and 21
patients with bilateral stenosis were managed medically.
Twelve patients with bilateral disease underwent angio-
plasty or open revascularization.
The overall 2-year estimated mortality was 32%. Mor-
tality was the same for patients treated with renal artery
intervention or treated medically. Most of the deaths were
due to coronary artery disease; however, three (11%) died
of complications from renal failure. Two of these deaths
occurred in patients with unilateral RVD, suggesting renal
parenchymal disease rather than ischemic nephropathy.
No change occurred inmedian blood pressure, number
of antihypertensive agents, or renal size on follow-up
Table III. Prospective angiographic natural history studie
Year
Patients
(n)
Renal
arteries
(n)
Mean
follow-up
(months)
Anatomic
progression
(% patients)
Dean25 1981 41 — 44 17 
Plouin26 1998 26 — 6 — 
Webster27 1998 30 — — 13† 
van Jaarsveld28 2000 50 100 12 20 
Pillay29 2002 85 159 30 — 
SCr, Serum creatinine; GFR, glomerular filtration rate; NS, not significant.
*50% increase, data for 30 patients.
†Of eight patients with serial angiography.
‡From referral to last follow-up.
§Unilateral group had significant increase, bilateral group did not.
Table IV. Prospective duplex sonography natural history
Year
Patients
(n)
Kidneys
(n)
Mean
follow-up
(months)
Anatomic
progression
(% arteries)
P
t
(
Zierler30 1994 80 134 13 8* 
Zierler14 1996 76 132 32 20 
Caps31 1998 170 295 33 31
Caps32 1998 122 204 33 —
SCr, Serum creatinine; GFR, glomerular filtration rate.
*Progression at 12 months.
†Seven subjects with bilateral atrophy increased 0.33 mg/dL/year; remaindamong survivors. During the study period, a small butstatistically significant increase in serum creatinine levels
was observed in patients with both unilateral and bilateral
RVD who underwent renal artery intervention. Patients
with bilateral RVD treated medically had stable serum
creatinine levels over 2 years. Although this study lacked a
specific measure of glomerular filtration, it demonstrated
stable renal length and stable serum creatinine levels, with
controlled hypertension in medically managed patients
who had bilateral RVD but no clinical indication for renal
artery intervention.
The available prospective duplex ultrasound studies of
RVD are summarized in Table IV. A series of consecutive
reports described prospective investigation performed at
the University of Washington.14,30-32 These authors first
reported on serial renal duplex sonography examinations
performed on 80 patients with hypertension.30 Renal arter-
ies were classified according to four categories: normal,
stenosis of 60%, stenosis of 60%, or renal artery occlu-
sion. The rate of progression to 60% stenosis during
3 years of follow-up was 8% for renal arteries that were
initially classified as normal and 43% for arteries initially
classified as having60% diameter-reducing stenosis. Inci-
dent renal artery occlusions were observed only in arteries
previously classified as having 60% diameter-reducing
stenosis. The 3-year risk for occlusion among the group was
7%. Factors associated with lesion progression included
increasing patient age, increasing systolic blood pressure,
smoking, female sex, and poorly controlled hypertension.
therosclerotic renal artery stenosis
gression
cclusion
arteries)
Blood
pressure
change
Decrease in
renal length
(% patients)
SCr
increase
(% patients)
GFR
decline
(% of patients)
12 — 37 46 3*
— 24/12 — NS NS
0† 28/16‡ — NS —
5 17/7 — NS NS
— NS NS § —
es of atherosclerotic renal artery stenosis
ssion
usion
eries)
Blood
pressure
change
Decrease in
renal length 1 cm
(% arteries)
SCr
increase
(% patients)
GFR
decline
(% patients)
 — 8 — —
 — — — —
— — — —
— 16 † —
re NS.s of a
Pro
to o
(%studi
rogre
o occl
% art
3
7
3
2Unfortunately, the number of study participants and the
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meaningful exploration of associations with significant
change.
In this study from the University of Washington, a
principle criterion for disease progression from60% renal
artery stenosis to60% renal artery stenosis was an increase
in the renal-aortic ratio (the ratio of RA-PSVs to aortic
PSV) value to 3.5 among subjects with RA-PSV 1.8
m/s.30 However, we have observed no association between
RA-PSV and aortic PSV in the presence or absence of
significant RVD in either population-based or clinical stud-
ies. Rather, the renal-aortic ratio can be considered an
example of a spurious correlation. The association with the
presence or absence of RVD resides entirely with RA-PSV.
This interpretation is supported from 834 renal duplex
exams performed initially among the Forsyth County CHS
cohort (Fig).3 Analysis from this cohort showed no rela-
tionship between aortic PSV and RA-PSV. Considered in
light of these data, the patients with estimated stenosis of
60% based on a renal-aortic ratio of 3.5 but with a
RA-PSV 1.8 m/sec could be considered to have signifi-
cant RVD at baseline.
Perhaps the most informative prospective study of
RVD using RDS was provided by Capps et al,31 who
described 5-year follow-up on 170 patients and 295 kid-
neys. In this extended report, disease progression was de-
fined by a 100 cm/s increase RA-PSV or progression to
occlusion. By these criteria, disease progression was de-
tected in 91 (31%) of the renal arteries in this study. Nine
arteries (3%) progressed to occlusion, and all of these were
considered to be diseased at the baseline RDS. The authors
created a model to predict the 2-year cumulative incidence
Renal artery peak systolic velocity (PVS) vs aortic PSV for the 834
Forsyth County participants in the Cardiovascular Health Study.of RVD progression. For renal arteries without ipsilateral orcontralateral stenosis in a nondiabetic patient with systolic
blood pressure (SBP) 160 mm Hg, the calculated risk of
progression at 2 years was 7%. For arteries with high-grade
ipsilateral and contralateral disease in a diabetic patient with
a SBP 160 mm Hg, the risk was estimated at 65%. In
contrast to these data among hypertensive patients, our
population-based study suggests a much lower rate of
significant change in RVD even though the criterion for
significant change (ie, 45 cm/s change in RA-PSV) was less
than half the criterion adopted by these authors.
The data reviewed in this report are frequently cited as
rationale for intervention for RVD discovered incidentally
during assessment of cardiac or vascular disease.1 However,
if one considers the potential value of prophylactic renal
artery intervention in light of the associated risks in a
normotensive individual without renal insufficiency, the
unique benefit from prophylactic renal artery intervention
is not justified.33 Moreover, when considered in terms of
the data provided by the current study, there appears to be
no justification for prophylactic renal artery intervention,
either as an open operative procedure performed in combi-
nation with aortic repair or as an independent catheter-
based intervention.
Although this prospective study provides unique data,
it suffers from a number of limitations. The index partici-
pants for CHS were selected through a two-step random
process that included eligible members from the sampled
individual’s household. Although this strategy was adopted
to enhance recruitment and retention, the final CHS co-
hort consisted of 70% of individuals initially sampled and
30% who shared the same household. Significant differ-
ences existed between randomly selected participants and
those who chose not to participate in the CHS. The refusal
rate was higher among women compared with men, al-
though a notably higher percentage of women participated
in the study.
The enrolled participants were younger, more highly
education, more likely to be married, and less likely to be
smokers.11 This “healthy cohort effect” may have contrib-
uted to a decreased rate of progression of RVD and may
have led to a potential survivorship effect. In previous reports,
prevalent RVD has demonstrated significant and indepen-
dent associations with both prevalent cardiovascular disease
and subsequent adverse cardiovascular events.18,34-35
Finally, this prospective study was constructed with
assumptions not met by observation. This study was origi-
nally constructed to include 300 participants, anticipating a
20% rate of progression during follow-up. However, a
number of factors, including outdated follow-up informa-
tion with the closure of the CHS, advanced participant age,
and changes in participants’ overall clinical conditions ham-
pered our patient recruitment for the second RDS. Conse-
quently, participant recruitment was less than half of that
projected. When considered collectively, these limitations
may have led to underestimation of RVD progression.
Another area of potential limitation with our method-
ology is the progression of RVD as defined by changes in
RA-PSV. Progression of RVD at the subcritical level was
JOURNAL OF VASCULAR SURGERY
Volume 44, Number 5 Pearce et al 961defined by changes in PSV greater than twice the standard
deviation of predicted change (RA-PSV 45 cm/s). This
predicted change in PSV was determined by using 281age-
matched individuals with two or more studies over a me-
dian follow-up of 2 years. Ninety-five percent of these
patients were hypertensive, 37% had a history of tobacco
use, and men comprised higher percentage of participants
(49%). Thus, the comparison group likely had a high rate of
atherosclerotic vascular disease and may presumably have
had a greater expected rate of RVD progression. Moreover,
the variability of the estimated change in PSV among the
independent cohort may be greater than that among the
CHS group, thereby underestimating progression of RVD
by this definition.
The observation of a significant decrease in RA-PSV in
23 kidneys deserves special comment. Because of the num-
ber of participants and the extended period of follow-up,
three registered vascular technologists participated in the
study. One technologist participated in both the first and
second RDS examination, but two technologists partici-
pated in only one exam. Examination of interobserver
differences at the first RDS suggested significant differences
between technologists. Although the apparent bias associ-
ated with each sonographer was consistent, this bias may
have contributed to an observed decrease in PSV when
different sonographers performed the first and second
RDS. In addition, significant technical improvements oc-
curred in RDS during the course of study. Compared with
the first RDS examination, the second study utilized tech-
nology that provided greater spatial resolution. Moreover,
color-flow Doppler imaging, which was not available at the
initial study, was used routinely to estimate the angle of
insonation at the second study. Considered collectively,
these differences may have contributed to the observed
decline in RA-PSV.
Despite these potential limitations, the study of the
Forsyth CHS cohort allows for longitudinal follow-up of a
large, diffuse group of community-dwelling black and
white men and women. As our population ages and as
advanced imaging techniques define incidental vascular
disease, anticipated RVD progression may be best esti-
mated by change in RVD observed in this CHS cohort.
CONCLUSION
This prospective, population-based evaluation of prev-
alent RVD among free-living, elderly Americans suggests
that the rate of significant changes in RVD is low. This low
rate of progression, combined with no observed progres-
sion in significant RVD to renal artery occlusion, does not
justify prophylactic intervention for asymptomatic renovas-
cular disease in the elderly.
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Dr R. James Valentine (Dallas, Texas). The purpose of this
study was to determine the incidence and natural history of inci-
dental renal artery stenoses in the general population of elderly
patients. The study methods are sound, and the excellent technical
results are commendable. Vascular surgeons should take note of
the criterion used to define a hemodynamically significant renal
artery stenosis. A peak systolic velocity of 1.8 m/s or more was
chosen after many years of laboratory and clinical investigation,
and it has been validated with renal arteriography. The Wake
Forest group has one of the largest experiences with renal artery
disease in the United States. The fact that 99% of their scans were
technically satisfactory attests to their expertise in renal artery
ultrasound.
The authors did a nice job of sampling the elderly population
in the initial study, and recruiting limitations are acknowledged in
themanuscript. However, only 14% of the original cohort returned
for the second renal artery duplex examination, which represents
less than 20% of the survivors in the Cardiovascular Health Study.
This brings me to my first question: what happened to the other
80%? After 8 years, important differences may have emerged be-
tween the recruited and non-recruited subjects, challenging the
notion that the study subjects represent the general population.
My second question relates to the 224 subjects who died after
the initial study. At this meeting 13 years ago, we reported that
incidental renal artery stenoses represent a marker for coronary
artery disease in vascular patients. Did the deceased subjects have a
higher incidence of renal artery disease than the survivors?
The take-home message from the present data is this: if you
find an incidental renal artery stenosis in an elderly patient, leave it
alone. Few lesions will progress. New, hemodynamically significant
lesions can be expected to develop in less than 5% of patients.
However, new lesions were significantly associated with an increasebrings me to my final question: could the affected patients have
been identified on the basis of worsening hypertension or rising
creatinine?
Dr Jeffrey Pearce. We practice and believe the results of the
study support the continued observation and not intervention for
incidentally found asymptomatic renal artery lesions, particularly in
those patients with normal or well-controlled blood pressure and
preserved renal function.
With regard to your first question, you correctly noted that
80% of the surviving participants did not return for a second
duplex. With the use of our institution’s GCRC, we attempted to
contact all surviving participants. Unfortunately with closure of the
CHS and lack of further annual follow-up exams, some of the
contact information was inaccurate. Furthermore, many of these
octogenarians are now living in nursing facilities, limiting their
ability to participate in the exam.
Regarding the question on the prevalence of RVD in those
surviving participants, I cannot give you a definitive answer but I
might be able to shed some light on the issue. We have previously
reported a twofold increase of subsequent cardiovascular events in
participants with RVD, even when controlling for prevalent car-
diovascular risk factors. Though the presence of RVD did not
confer an overall survival disadvantage, we believe these partici-
pants are having more cardiac events. Thus, some of them may
have succumbed in the study interval due to cardiac disease.
And then finally with regard to your question on patient
screening for duplex examinations, we looked critically at those
participants that had RVD in this cohort and none of these
participants smelled of renovascular disease. None of them had
severe hypertension. None of them had renal insufficiency. There-
fore, none of these participants would have met our screening
criteria, which is for those folks with worsening uncontrolled or
severe hypertension or with progressive renal insufficiency.
